Lerdelimumab

Names

[ Name ]:
Lerdelimumab

Biological Activity

[Description]:

Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2].

[Related Catalog]:

Signaling Pathways >> Stem Cell/Wnt >> TGF-beta/Smad

Signaling Pathways >> TGF-beta/Smad >> TGF-beta/Smad

Research Areas >> Neurological Disease

[In Vitro]

Lerdelimumab (10 μg/mL) 抑制 TGF-β2 诱导的所有作用，如：抑制 TGF-β2 刺激被膜袋转分化和收缩，诱导被膜袋的 MMP-2 和 -9 的释放[2]。

[In Vivo]

Lerdelimumab (100 μL，1 mg/mL；结膜下注射；在术后第 2、3、4、7、9、11 和 14 天) 明显改善青光眼手术结果，降低角膜副作用的风险[1]。

[References]

[1]. Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401.

[2]. Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci.

Chemical & Physical Properties

No Any Chemical & Physical Properties